# UAP1

## Overview
UAP1 is a gene that encodes the enzyme UDP-N-acetylglucosamine pyrophosphorylase 1, which is a key player in the hexosamine biosynthetic pathway. This enzyme is categorized as a nucleotide-binding protein due to its central catalytic domain that adopts a Rossmann fold, a structural motif common in such proteins (Peneff2001Crystal). UAP1 is responsible for catalyzing the conversion of UTP and N-acetylglucosamine-1-phosphate into UDP-N-acetylglucosamine (UDP-GlcNAc) and pyrophosphate, a reaction crucial for various glycosylation processes that affect protein stability and function (Chen2020A). The gene is expressed in multiple isoforms due to alternative splicing, which can influence the enzyme's activity and structural configuration (Peneff2001Crystal). UAP1's role is evolutionarily conserved, underscoring its importance in cellular metabolism and homeostasis (Itkonen2014UAP1).

## Structure
The human UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) protein is characterized by a complex molecular structure that includes several distinct domains and motifs. The protein features a central catalytic domain that adopts a Rossmann fold, a common structural motif in nucleotide-binding proteins, which is crucial for its enzymatic activity (Peneff2001Crystal). This domain is flanked by N-terminal and C-terminal regions, which contribute to the overall stability and function of the enzyme. The active site of UAP1 is lined with positively charged residues, such as Lys122, Lys407, and Arg115, which are essential for substrate binding and catalysis (Peneff2001Crystal).

UAP1 exists in multiple isoforms due to alternative splicing, which results in structural variations that can affect its oligomeric assembly and active site architecture. Specifically, a 17-residue segment introduced by alternative splicing in one isoform influences its dimerization and enzymatic activity (Peneff2001Crystal). The protein may also undergo post-translational modifications, such as phosphorylation, which can regulate its function and interactions within the cell. These structural features and modifications are critical for the enzyme's role in the biosynthesis of UDP-N-acetylglucosamine, a key substrate in glycosylation processes.

## Function
UAP1 (UDP-N-acetylglucosamine pyrophosphorylase 1) is an enzyme that plays a crucial role in the hexosamine biosynthetic pathway (HBP), which is essential for the production of UDP-N-acetylglucosamine (UDP-GlcNAc). This compound serves as a substrate for various glycosylation processes, including O-GlcNAcylation, glycosylphosphatidylinositol (GPI) anchor synthesis, heparan sulfate synthesis, and N-linked glycosylation. These processes are vital for protein stability, processing, and function, impacting cell signaling, transcription, and nutrient sensing (Chen2020A).

UAP1 catalyzes the conversion of UTP and N-acetylglucosamine-1-phosphate into UDP-GlcNAc and pyrophosphate, maintaining a steady supply of cytoplasmic UDP-GlcNAc. This supply is critical for normal cellular physiology and development, supporting processes like O-GlcNAcylation, a post-translational modification that influences various cellular functions (Chen2020A).

The enzyme is active in the cytoplasm and is essential for maintaining cellular homeostasis and normal physiological functions. It is involved in the synthesis of glycoproteins and glycolipids, which are important for cell signaling, adhesion, and structural integrity (Chen2020A). UAP1's function is evolutionarily conserved, highlighting its fundamental role in cellular metabolism (Itkonen2014UAP1).

## Clinical Significance
Mutations and alterations in the UAP1 gene have significant clinical implications. The A229T missense mutation in UAP1 is associated with developmental delay and intellectual disability. This mutation affects the AGX1 enzyme, leading to decreased stability and catalytic efficiency, which disrupts the production of UDP-GlcNAc, a crucial substrate for glycosylation processes. The mutation causes structural changes in the enzyme, impacting interactions essential for its function, and is predicted to be pathogenic, potentially contributing to developmental disorders similar to OGT-linked Congenital Disorders of Glycosylation (Chen2020A).

In cancer, UAP1 is frequently overexpressed, particularly in prostate and urinary bladder cancers. In prostate cancer, high UAP1 expression is linked to resistance against inhibitors of N-linked glycosylation, providing a growth advantage by protecting cancer cells from endoplasmic reticulum stress. This overexpression is associated with tumor progression and may serve as a therapeutic target (Itkonen2014UAP1). In urinary bladder cancer, UAP1 gene amplification and overexpression correlate with poor clinical outcomes and advanced disease stages, suggesting its role in cancer aggressiveness and as a potential prognostic marker (Cui2022Identification).


## References


[1. (Chen2020A) Xiping Chen, Olawale G. Raimi, Andrew T. Ferenbach, and Daan M.F. van Aalten. A missense mutation in a patient with developmental delay affects the activity and structure of the hexosamine biosynthetic pathway enzyme agx1. FEBS Letters, 595(1):110–122, November 2020. URL: http://dx.doi.org/10.1002/1873-3468.13968, doi:10.1002/1873-3468.13968. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/1873-3468.13968)

[2. (Peneff2001Crystal) C. Peneff. Crystal structures of two human pyrophosphorylase isoforms in complexes with udpglc(gal)nac: role of the alternatively spliced insert in the enzyme oligomeric assembly and active site architecture. The EMBO Journal, 20(22):6191–6202, November 2001. URL: http://dx.doi.org/10.1093/emboj/20.22.6191, doi:10.1093/emboj/20.22.6191. This article has 129 citations.](https://doi.org/10.1093/emboj/20.22.6191)

[3. (Itkonen2014UAP1) H M Itkonen, N Engedal, E Babaie, M Luhr, I J Guldvik, S Minner, J Hohloch, M C Tsourlakis, T Schlomm, and I G Mills. Uap1 is overexpressed in prostate cancer and is protective against inhibitors of n-linked glycosylation. Oncogene, 34(28):3744–3750, September 2014. URL: http://dx.doi.org/10.1038/onc.2014.307, doi:10.1038/onc.2014.307. This article has 73 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/onc.2014.307)

[4. (Cui2022Identification) Yangyan Cui, Hanyi Feng, Jiakuan Liu, Jiajun Wu, Rujian Zhu, Ruimin Huang, and Jun Yan. Identification of hexosamine biosynthesis pathway as a novel prognostic signature and its correlation with immune infiltration in bladder cancer. Frontiers in Molecular Biosciences, September 2022. URL: http://dx.doi.org/10.3389/fmolb.2022.1009168, doi:10.3389/fmolb.2022.1009168. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fmolb.2022.1009168)